The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2

Biochemical Journal

Volumn 381, Issue 3, 2004, Pages 685-691

  Matt, Theresia ^a   Martinez Yamout, Maria A ^a   Dyson, H Jane ^a   Wright, Peter E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

cAMP response element binding protein binding protein (CBP); Glutathione S transferase pull down; Mouse double minute protein (MDM2); Oncoprotein; Protein secondary structure; Zinc finger

Indexed keywords

DEGRADATION; PROTEINS; SPECTROSCOPIC ANALYSIS; TUMORS;

SIGNAL TRANSDUCERS; TUMOR SUPPRESSORS;

BIOCHEMISTRY;

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EDETIC ACID; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; LIGASE; PEPTIDE FRAGMENT; PROTEIN CITED2; PROTEIN MDM2; PROTEIN P300; PROTEIN P53; STAT2 PROTEIN; TRANSACTIVATOR PROTEIN; UBIQUITIN PROTEIN LIGASE HDM2; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CIRCULAR DICHROISM; COMPLEX FORMATION; IN VITRO STUDY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE;

ANIMALS; CIRCULAR DICHROISM; CLONING, MOLECULAR; CREB-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; ESCHERICHIA COLI; GLUTATHIONE TRANSFERASE; HUMANS; MICE; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATORS; TRANSFECTION; ZINC FINGERS;

EID: 4344682825     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20040564     Document Type: Article

References (53)

1. Goodman, R. H. and Smolik, S. (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553-1577
2. Janknecht, R. and Hunter, T. (1996) Transcription: a growing coactivator network. Nature (London) 383, 22-23
3. Giles, R. H., Peters, D. J. and Breuning, M. H. (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14, 178-183
4. Shikama, N., Lyon, J. and LaThangue, N. B. (1997) The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 7, 230-236
5. De Guzman, R. N., Liu, H. Y., Martinez-Yamout, M., Dyson, H. J. and Wright, P. E. (2000) Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J. Mol. Biol. 303, 243-253
6. Ponting, C. P., Blake, D. J., Davies, K. E., Kendrick-Jones, J. and Winder, S. J. (1996) ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Trends Biochem. Sci. 21, 11-13
7. Goto, N. K., Zor, T., Martinez-Yamout, M., Dyson, H. J. and Wright, P. E. (2002) Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP): the mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain. J. Biol. Chem. 277, 43168-43174
8. De Guzman, R. N., Martinez-Yamout, M. A., Dyson, H. J. and Wright, P. E. (2004) Structure and function of the CBP/p300 TAZ domains. In Zinc Finger Proteins: from Atomic Contact to Cellular Function (luchi, S. and Kuldell, N., eds.), in the press, Landes Bioscience, Georgetown
9. Dames, S. A., Martinez-Yamout, M., De Guzman, R. N., Dyson, H. J. and Wright, P. E. (2002) Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. U.S.A. 99, 5271-5276
10. Freedman, S. J., Sun, Z. Y., Kung, A. L., France, D. S., Wagner, G. and Eck, M. J. (2003) Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2. Nat. Struct. Biol. 10, 504-512
11. Freedman, S. J., Sun, Z. Y., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G. and Eck, M. J. (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α. Proc. Natl. Acad. Sci. U.S.A. 99, 5367-5372
12. De Guzman, R. N., Martinez-Yamout, M. A., Dyson, H. J. and Wright, P. E. (2004) Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of C1TED2: regulation by competition between intrinsically unstructured ligands for non-identical binding sites. J. Biol. Chem. 279, 3042-3049
13. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G. and Livingston, D. M. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6, 1335-1340
14. Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323-331
15. Sionov, R. V. and Haupt, Y. (1999) The cellular response to p53: the decision between life and death. Oncogene 18, 6145-6157
16. Vousden, K. H. and Lu, X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604
17. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. and Weissman, A. M. (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951
18. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27
19. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature (London) 387, 296-299
20. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. (1997) Regulation of p53 stability by Mdm2. Nature (London) 387, 299-303
21. Chen, J., Lin, J. and Levine, A. J. (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1, 142-152
22. Mornand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245
23. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J. and Pavletich, N. P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953
24. Schon, O., Friedler, A., Bycroft, M., Freund, S. M. and Fersht, A. R. (2002) Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323, 491-501
25. Gu, W., Shi, X. L. and Boeder, R. G. (1997) Synergistic activation of transcription by CBP and p53. Nature (London) 387, 819-823
26. Grossman, S. R. (2001) p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268, 2773-2778
27. Song, C. Z., Keller, K., Chen, Y., Murata, K. and Stamatoyannopoulos, G. (2002) Transcription coactivator CBP has direct DNA binding activity and stimulates transcription factor DNA binding through small domains. Biochem. Biophys. Res. Commun. 296, 118-124
28. Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S. and Kelly, K. (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89, 1175-1184
29. Van Orden, K., Giebler, H. A., Lemasson, I., Gonzales, M. and Nyborg, J. K. (1999) Binding of p53 to the KIX domain of CREB binding protein: a potential link to human T-cell leukemia virus, type I-associated leukemogenesis. J. Biol. Chem. 274, 26321-26328
30. Livengood, J. A., Scoggin, K. E., Van Orden, K., McBryant, S. J., Edayathumangalam, R. S., Laybourn, P. J. and Nyborg, J. K. (2002) p53 transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J. Biol. Chem. 277, 9054-9061
31. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M. and Livingston, D. M. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2, 405-415
32. Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y. and Livingston, D. M. (2003) Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344
33. Demarest, S. J., Martinez-Yamout, M., Chung, J., Chen, H., Xu, W., Dyson, H. J., Evans, R. M. and Wright, P. E. (2002) Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature (London) 415, 549-553
34. Gill, S. C. and von Hippel, P. H. (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319-326
35. Bell, S., Klein, C., Muller, L., Hansen, S. and Buchner, J. (2002) p53 contains large unstructured regions in its native state. J. Mol. Biol. 322, 917-927
36. Dawson, R., Mueller, I., Dehner, A., Klein, C., Kassler, H. and Buchner, J. (2003) The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 332, 1131-1141
37. Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B. and Hung, M. C. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982
38. Chen, J., Marechal, V. and Levine, A. J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107-4114
39. Bhattacharya, S., Michels, C. L., Leung, M. K., Arany, Z. P., Kung, A. L. and Livingston, D. M. (1999) Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13, 64-75
40. Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z., D'Andrea, A. and Livingsion, D.M. (1996) Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α. Nature (London) 383, 344-347
41. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. and Howley, P. M. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136
42. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. and Howley, P. M. (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505
43. Beer-Romero, P., Glass, S. and Rolfe, M. (1997) Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 14, 595-602
44. Talis, A. L., Huibregtse, J. M. and Howley, P. M. (1998) The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273, 6439-6445
45. Nakamura, S., Roth, J. A. and Mukhopadhyay, T. (2002) Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells. Oncogene 21, 2605-2610
46. Camus, S., Higgins, M., Lane, D. P. and Lain, S. (2003) Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett. 536, 220-224
47. Li, X. and Coffino, P. (1996) High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70, 4509-4516
48. Gu, J., Rubin, R. M. and Yuan, Z. M. (2001) A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. Oncogene 20, 3519-3527
49. Wadgaonkar, R. and Collins, T. (1999) Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. 274, 13760-13767
50. Kobet, E., Zeng, X., Zhu, Y., Keller, D. and Lu, H. (2000) MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. U.S.A. 97, 12547-12552
51. Jin, Y., Zeng, S. X., Dai, M. S., Yang, X. J. and Lu, H. (2002) MDM2 inhibits PCAF (p300/CREB-binding protein-associatedfactor)-mediated p53 acetylation. J. Biol. Chem. 277, 30838-30843
52. Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, Jr, W. G., Oren, M., Chen, J. and Lu, H. (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell Biol. 19, 3257-3266
53. Kadakia, M., Brown, T. L., McGorry, M. M. and Berberich, S. J. (2002) MdmX inhibits Smad transactivation. Oncogene 21, 8776-8785